Ascent Therapeutics

About:

Ascent Therapeutics offers Pepducins targeting GPCRs on the cell membrane, expanding the GPCR frontier.

Website: http://www.ascentrx.com

Top Investors: Novartis Venture Fund, TVM Capital, HealthCare Ventures

Description:

Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.